Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis

Lymphoma

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Oncotarget.

Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D, Chae YK

doi: 10.18632/oncotarget.25154.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Non-small-cell lung cancer immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis

J Thorac Oncol.

Lurienne L, Cervesi J, Duhalde L, de Gunzburg J, Andremont A, Zalcman G, Buffet R, Bandinelli PA

doi: 10.1016/j.jtho.2020.03.002.

Gastrointestinal CancerLung, Respiratory and Thoracic Cancer

Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis

Int J Cancer.

Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J

doi: 10.1002/ijc.30691.

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Lung, Respiratory and Thoracic CancerLymphoma

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Lancet Oncol.

Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E

doi: 10.1016/S1470-

Lung, Respiratory and Thoracic Cancer

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

JAMA Oncol.

Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC

doi: 10.1001/

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis

Lung Cancer.

Dafni U, Tsourti Z, Vervita K, Peters S

doi: 10.1016/j.lungcan.

Lung, Respiratory and Thoracic Cancer

RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance

doi: 10.1186/s12885-018-5070-6.

Lung, Respiratory and Thoracic CancerLymphoma

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Lancet.

Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr

doi: 10.1016/

Related content

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Non-small-cell lung cancer immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis

Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis

RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study